Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Apr;33(4):562–565. doi: 10.1128/aac.33.4.562

Multicenter in vitro evaluation of SM-7338, a new carbapenem.

R N Jones 1, K E Aldridge 1, S D Allen 1, A L Barry 1, P C Fuchs 1, E H Gerlach 1, M A Pfaller 1
PMCID: PMC172479  PMID: 2658796

Abstract

A new carbapenem, SM-7338, was compared with imipenem, cefotaxime, and ceftazidime at five medical centers. Nearly 6,000 strains were tested by reference methods of the National Committee for Clinical Laboratory Standards, and SM-7338 inhibited the largest percentage of gram-negative bacilli. Its spectrum included all members of the family Enterobacteriaceae (99.7% were susceptible to less than or equal to 4 micrograms/ml), Pseudomonas spp. (but not Xanthomonas maltophilia), and Acinetobacter spp. The potency and spectrum of SM-7338 against the gram-positive organisms were less than those of imipenem and superior to those of ceftazidime. Only the enterococci and some oxacillin-resistant staphylococci were less susceptible to SM-7338 (MICs for 90% of isolates, greater than or equal to 8 micrograms/ml). Organisms resistant to ceftazidime were generally susceptible to SM-7338 and imipenem (76%). However, for one-third of the imipenem-resistant gram-negative bacilli (MICs, greater than 8 micrograms/ml), SM-7338 MICs were less than or equal to 4 micrograms/ml. Some endemic differences in patterns of SM-7338 activity against selected gram-negative species were found among some medical centers.

Full text

PDF
562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N. Bacterial antibiotic resistance before and after clinical application in the United States. Bull N Y Acad Med. 1987 Apr;63(3):217–230. [PMC free article] [PubMed] [Google Scholar]
  2. Basker M. J., Boon R. J., Hunter P. A. Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383. J Antibiot (Tokyo) 1980 Aug;33(8):878–884. doi: 10.7164/antibiotics.33.878. [DOI] [PubMed] [Google Scholar]
  3. Jones R. N., Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis. 1982 Sep-Oct;4 (Suppl):S300–S315. doi: 10.1093/clinids/4.supplement_2.s300. [DOI] [PubMed] [Google Scholar]
  4. Kahan F. M., Kropp H., Sundelof J. G., Birnbaum J. Thienamycin: development of imipenen-cilastatin. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):1–35. doi: 10.1093/jac/12.suppl_d.1. [DOI] [PubMed] [Google Scholar]
  5. Kropp H., Sundelof J. G., Hajdu R., Kahan F. M. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982 Jul;22(1):62–70. doi: 10.1128/aac.22.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Nakayama M., Iwasaki A., Kimura S., Mizoguchi T., Tanabe S., Murakami A., Watanabe I., Okuchi M., Itoh H., Saino Y. Carpetimycins A and B, new beta-lactam antibiotics. J Antibiot (Tokyo) 1980 Nov;33(11):1388–1390. doi: 10.7164/antibiotics.33.1388. [DOI] [PubMed] [Google Scholar]
  7. Neu H. C., Chin N. X., Saha G., Labthavikul P. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother. 1986 Dec;30(6):828–834. doi: 10.1128/aac.30.6.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Okamura K., Hirata S., Okumura Y., Fukagawa Y., Shimauchi Y., Kouno K., Ishikura T. PS-5, a new beta-lactam antibiotic from Streptomyces. J Antibiot (Tokyo) 1978 May;31(5):480–482. doi: 10.7164/antibiotics.31.480. [DOI] [PubMed] [Google Scholar]
  9. Petit A., Sirot D. L., Chanal C. M., Sirot J. L., Labia R., Gerbaud G., Cluzel R. A. Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1988 May;32(5):626–630. doi: 10.1128/aac.32.5.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shibamoto N., Koki A., Nishino M., Nakamura K., Kiyoshima K., Okamura K., Okabe M., Okamoto R., Fukagawa Y., Shimauchi Y. PS-6 and PS-7, new beta-lactam antibiotics. Isolation, physicochemical properties and structures. J Antibiot (Tokyo) 1980 Oct;33(10):1128–1137. doi: 10.7164/antibiotics.33.1128. [DOI] [PubMed] [Google Scholar]
  11. Shibamoto N., Nishino M., Okamura K., Fukagawa Y., Ishikura T. PS-8, a minor carbapenem antibiotic. J Antibiot (Tokyo) 1982 Jun;35(6):763–765. doi: 10.7164/antibiotics.35.763. [DOI] [PubMed] [Google Scholar]
  12. Tanaka K., Shoji J., Terui Y., Tsuji N., Kondo E., Mayama M., Kawamura Y., Hattori T., Matsumoto K., Yoshida T. Asparenomycin A, a new carbapenem antibiotic. J Antibiot (Tokyo) 1981 Jul;34(7):909–911. doi: 10.7164/antibiotics.34.909. [DOI] [PubMed] [Google Scholar]
  13. Tsuji N., Nagashima K., Kobayashi M., Terui Y., Matsumoto K., Kondo E. The structures of pluracidomycins, new carbapenem antibiotics. J Antibiot (Tokyo) 1982 Apr;35(4):536–540. doi: 10.7164/antibiotics.35.536. [DOI] [PubMed] [Google Scholar]
  14. Wise R. In vitro and pharmacokinetic properties of the carbapenems. Antimicrob Agents Chemother. 1986 Sep;30(3):343–349. doi: 10.1128/aac.30.3.343. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES